EVERNORTH HEALTH SERVICES

Express Scripts® Pharmacy Benefit Services
Pharmacy and Therapeutics (P&T) Committee
Proceedings
September 17, 2026

New Drug Evaluations

The Committee reviewed the following new drugs:

A. **Epioxa™/Epioxa™ HD (riboflavin 5'-phosphate 0.177%/0.239% ophthalmic solution)** Avedro/Glaukos
B. **Genglycos™ (pariglasgene brecaparvovec-opnr intravenous infusion)** Ultragenyx
C. **Jideytro™ (zidesamtinib tablets)** Nuvation Bio
D. **Lipfendra® (enlicitide tablets)** Merck
E. **Lisraya® (brepocitinib tablets)** Priovant
F. **Lytenava™ (bevacizumab-vikg intravitreal injection)** Outlook Therapeutics
G. **mFlusiva® (influenza vaccine intramuscular injection [mRNA])** Moderna
H. **Mimrylo™ (rusfertide subcutaneous injection)** Takeda
I. **Pasatru™ (garetosmab-grts intravenous infusion)** Regeneron
J. **Rasonque™ (daraxonrasib tablets)** Revolution Medicines
K. **Revtorpyk™ (gedatolisib intravenous infusion)** Celcuity
L. **Sarclisa Escena™ (isatuximab-irfc subcutaneous injection)** Sanofi Aventis
M. **Trutakna™ (atacicept-vymj subcutaneous injection)** Vera
N. **Tudriqev™ (vusolimogene oderparepvec-wtpg intratumor injection)** Replimmune
O. **Zenbexus™ (iberdomide capsules)** Bristol Myers Squibb

New Indications for Existing Products

The Committee reviewed the following new or changes to indications for existing products: See product inserts for specific wording.

A. **Augmentin® (amoxicillin and clavulanate potassium tablets, oral suspension, chewable tablets, and extended-release tablets [various strengths])** GlaxoSmithKline/US Antibiotics, generics – Updates to indications and usage wording in various Augmentin products (tablets, extended-release tablets, chewable tablets, oral suspension) which applies to many indications for the treatment of infections caused by designated susceptible beta-lactamase-producing microorganisms (e.g., lower respiratory tract infections, community acquired pneumonia, acute bacterial sinusitis, acute bacterial otitis medica, recurrent or persistent acute otitis media, skin and skin structure infections, urinary tract infections).
B. **Besremi® (ropeginterferon alfa-2b-njft subcutaneous injection)** PharmaEssentia – New indication for the treatment of essential thrombocythemia in adults.
C. **Bkemv® (eculizumab-aeeb intravenous infusion)** Amgen – New indication for the treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody positive.
D. **Casgevy® (exagamglogene autotemcel intravenous infusion)** Vertex – Expanded age indication for the treatment of sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia in patients ≥ 2 years of age.

© 2026 Evernorth Health Services. All Rights Reserved.

E. **Empaveli® (pegcetacoplan subcutaneous injection)** Apellis – Expanded indication to describe an additional benefit (to reduce the loss of kidney function), in patients with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The expanded indication is for the treatment of adults and pediatric patients ≥ 12 years of age with C3G or primary IC-MPGN, to reduce proteinuria and the loss of kidney function.
F. **Epysqli® (eculizumab-aagh intravenous injection)** Teva – New indication for the treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody positive.
G. **Fabhalta® (iptacopan capsules)** Novartis – Conversion of accelerated approval to traditional approval of Fabhalta to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression.
H. **Imaavy® (nipocalimab-aahu intravenous infusion)** Johnson & Johnson – New indication for the treatment of warm autoimmune hemolytic anemia in adult and pediatric patients ≥ 12 years of age with inadequate response to corticosteroids or immunosuppressive therapy.
I. **Keytruda® (pembrolizumab intravenous infusion)** Merck **and Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection)** Merck – Revised indication for use in urothelial cancer in combination with Padcev (enfortumab vedotin-ejfv IV infusion) as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of muscle invasive bladder cancer (MIBC) in adults.
J. **Krazati® (adagrasib tablets)** Bristol Myers Squibb – Withdrawal of the accelerated approval indication for use in combination with cetuximab, for the treatment of KRAS G12C-mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, in adults who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
K. **Leqembi IQLIK® (lecanemab-irmb subcutaneous injection)** Eisai – Initial therapy indication for the treatment of Alzheimer's disease.
L. **Lerochol® (lerodalcibep-liga subcutaneous injection)** LIB – Updated indication statement for Lerochol which is approved as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The added statement present in the indications and usage section states that cardiovascular (CV) outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors as an add-on to statin therapy.
M. **Mounjaro® (tirzepatide subcutaneous injection)** Eli Lilly – New indication as a treatment to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction MI, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
N. **Padcev® (enfortumab vedotin-ejfv intravenous infusion)** Astellas – Revised indication in combination with Keytruda (pembrolizumab IV infusion) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection) as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with MIBC.
O. **Pluvicto® (lutetium Lu 177 vipivotide tetraxetan intravenous infusion)** Novartis – New indication for metastatic androgen pathway modulation-naïve or sensitive prostate cancer in combination with androgen receptor pathway inhibitor therapy for the treatment of adults with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
P. **Retevmo® (selpercatinib tablets and capsules)** Lilly – Conversion from accelerated approval to traditional approval of Retevmo for the treatment of adult and pediatric patients ≥ 2 years of

© 2026 Evernorth Health Services. All Rights Reserved.

age with locally advanced or metastatic solid tumors with a rearranged during transfection gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Q. Ryaltris® (olopatadine and mometasone furoate monohydrate nasal spray) Glenmark – Expanded age indication for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients ≥ 6 years of age.

R. Stelara® (ustekinumab intravenous infusion and subcutaneous injection) Janssen/Johnson and Johnson – New indication for the treatment of moderately to severely active ulcerative colitis in pediatric patients ≥ 2 years of age.

S. Sunlenca® (lenacapavir subcutaneous injection and tablets) Gilead – New indication for Sunlenca tablets, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, for oral loading as a component of the initiation regimen for Bixlenvo (bictegravir/lenacapavir tablets), as a complete regimen for the treatment of HIV-1 infection, in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of Bixlenvo.

T. Tevimbra® (tislelizumab-jsgr intravenous infusion) BeOne Medicines – New indication in combination with Ziihera (zanidatamab-hrii IV infusion), fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for adults with human epidermal growth factor receptor 2-positive (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.

U. Tivicay PD® (dolutegravir tablets for oral suspension) Viiv Healthcare – Expanded indication based on age and weight to treat HIV-1 infection (in combination with other antiretroviral agents) in neonates from birth up to 4 weeks of age who weigh at least 2 kg. Previously, Tivicay and Tivicay PD were indicated to treat HIV-1 infection (in combination with other antiretroviral agents) in adults and in pediatric patients at least 4 weeks of age and weighing at least 3 kg.

V. Wilate® (von Willebrand factor/coagulation factor VIII Complex [human] injection) Octapharma – Expanded age indication for von Willebrand disease as routine prophylaxis to reduce the frequency of bleeding episodes in patients < 6 years of age.

W. Ziihera® (zanidatamab-hrii intravenous infusion) Jazz – New indication in combination with fluoropyrimidine- and platinum-containing chemotherapy and Tevimbra (tislelizumab-jsgr IV infusion) as first-line treatment for adults with human epidermal growth factor receptor 2-positive (IHC 3+ or IHC 2+/in situ hybridization [ISH]+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions:

A. Bixlenvo™ (bictegravir and lenacapavir tablets) Gilead
B. Cligavyx® (fulvestrant intramuscular injection) Teva
C. Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system) Viatris
D. Qlonilik® (clonidine oral solution) CMP Pharma

© 2026 Evernorth Health Services. All Rights Reserved.

New Biosimilars
The Committee reviewed the following new biosimilars:

A. **Garzulys™ (insulin aspart-fsan subcutaneous injection/infusion and intravenous infusion)** Meitheal/Emerge
B. **Zimrixby™ (rituximab-cdxx intravenous infusion)** Fresenius Kabi/Dr. Reddy's

© 2026 Evernorth Health Services. All Rights Reserved.